Axogen（AXGN）株式概要
は、その子会社とともに、末梢神経の再生と修復に使用される技術の開発と商業化を世界中で行っている。 詳細
AXGN Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Axogen, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$41.31 |
| 52週高値 | US$45.83 |
| 52週安値 | US$9.22 |
| ベータ | 1.17 |
| 1ヶ月の変化 | 15.10% |
| 3ヶ月変化 | 17.03% |
| 1年変化 | 277.61% |
| 3年間の変化 | 363.64% |
| 5年間の変化 | 102.80% |
| IPOからの変化 | 1,424.35% |
最新ニュース
Recent updates
ナラティブの更新 • May 04
AXGN: BLA Approval And New Market Entry Will Drive Upside Potential
Axogen's analyst price target has been raised from $41.22 to $50.78, with analysts pointing to updated assumptions around fair value, revenue growth, profit margins and recent Street research highlighting the impact of Avance Nerve Graft's BLA approval and commercial expansion opportunities. Analyst Commentary Recent Street research around Axogen clusters around the impact of Avance Nerve Graft's BLA approval, expanded market exposure and revised fair value assumptions, with a series of price target moves anchoring the discussion.分析記事 • Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
It's been a pretty great week for Axogen, Inc. ( NASDAQ:AXGN ) shareholders, with its shares surging 12% to US$41.77 in...ナラティブの更新 • Apr 18
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.ナラティブの更新 • Apr 01
AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.ナラティブの更新 • Mar 17
AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.ナラティブの更新 • Mar 03
AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.ナラティブの更新 • Feb 17
AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.ナラティブの更新 • Feb 02
AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.ナラティブの更新 • Jan 19
AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.ナラティブの更新 • Jan 04
AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.ナラティブの更新 • Dec 14
AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.ナラティブの更新 • Nov 30
AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.分析記事 • Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...ナラティブの更新 • Nov 16
AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.分析記事 • Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shares have continued their recent momentum with a 30% gain in the last month alone. The...ナラティブの更新 • Oct 31
AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.分析記事 • Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Those holding Axogen, Inc. ( NASDAQ:AXGN ) shares would be relieved that the share price has rebounded 29% in the last...新しいナラティブ • May 29
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.分析記事 • May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
Axogen, Inc. ( NASDAQ:AXGN ) shareholders that were waiting for something to happen have been dealt a blow with a 32...分析記事 • Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Axogen, Inc. ( NASDAQ:AXGN ) is a stock to...分析記事 • Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jan 07
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Summary Axogen has surged 204% in 12 months, driven by strong sales growth, margin expansion, and efficient capital utilization, offering a favorable risk/reward profile. I get to projected revenues of $280-$350M by FY'26E with NOPAT of $30-$40M, and a valuation range of $22-$28/share, providing 68% upside potential. AXGN's key growth drivers include successful new facility operations, Avance segment progress, and high adoption rates of Axoguard HA and Avive+ products. Read the full article on Seeking Alpha分析記事 • Dec 24
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Despite an already strong run, AxoGen, Inc. ( NASDAQ:AXGN ) shares have been powering on, with a gain of 28% in the...分析記事 • Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...株主還元
| AXGN | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 0.9% | 4.0% | -0.3% |
| 1Y | 277.6% | -18.6% | 26.7% |
業界別リターン: AXGN過去 1 年間で-18.6 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: AXGN過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| AXGN volatility | |
|---|---|
| AXGN Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: AXGN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AXGNの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 622 | Michael Dale | www.axogeninc.com |
Axogen, Inc.は、その子会社とともに、末梢神経の再生と修復に使用される技術の開発と商業化を世界中で行っている。同社は、末梢神経不連続部の外科的修復を目的とした加工神経移植片であるAvance Nerve Graft、切断された末梢神経末端を整列させ、緊張のない修復で接続するために使用されるコアプテーションエイドであるAxoguard Nerve Connector、損傷した末梢神経を保護し、包み込み、再建された神経の隙間を補強するために使用される製品であるAxoguard Nerve Protectorを提供している。また、末梢神経を非拘束的に保護する外科用インプラントであるAxoguard HA+ Nerve Protector、ブタ粘膜下層ECM製品であるAxoguard Nerve Cap、多層羊膜移植片であるAvive+ Soft Tissue Matrix、提供されたヒト末梢神経組織からAvance Nerve Graftを加工する技術であるAvance Methodも提供している。さらに、末梢神経組織の回収・取得、検査、ドナーのメディカルレビューとリリース、デブリードマンなどの処理工程、パッケージング、滅菌も提供している。同社は、病院、手術センター、軍病院に製品を提供し、国内の独立代理店を通じて、形成再建外科医、整形外科医、形成手外科医、特定の口腔・顎顔面外科医などの外科医に呼びかけている。本社はフロリダ州アラチュアにある。
Axogen, Inc. 基礎のまとめ
| AXGN 基礎統計学 | |
|---|---|
| 時価総額 | US$2.27b |
| 収益（TTM） | -US$31.45m |
| 売上高(TTM) | US$238.11m |
9.2x
P/Sレシオ-69.8x
PER（株価収益率AXGN は割高か？
公正価値と評価分析を参照収益と収入
| AXGN 損益計算書（TTM） | |
|---|---|
| 収益 | US$238.11m |
| 売上原価 | US$59.50m |
| 売上総利益 | US$178.61m |
| その他の費用 | US$210.06m |
| 収益 | -US$31.45m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.59 |
| グロス・マージン | 75.01% |
| 純利益率 | -13.21% |
| 有利子負債／自己資本比率 | 0% |
AXGN の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 23:35 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Axogen, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |